New Preclinical Study Finds Niagen® Prevents Light-Induced Retinal Damage in Mice

LOS ANGELES–(BUSINESS WIRE)—- $CDXC #CellularHealth–ChromaDex Corp. (NASDAQ:CDXC) today announced new preclinical research published in Investigative Ophthalmology & Visual Science finding Niagen® (patented nicotinamide riboside, or NR) prevented light-induced retinal damage in mice. This research paves the way for future preclinical and clinical studies exploring the relationship between NAD+ levels and preservation of long-term ocular health. The study, conducted through the ChromaDex External Research Program